Inmune Bio Inc (INMB)

Inmune Bio (INMB) Stock Price & Analysis


INMB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.63 - $10.75
Previous Close$6.74
Average Volume (3M)56.08K
Market Cap
Enterprise Value$120.42M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-4.4
May 18, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding17,945,995
10 Day Avg. Volume48,085
30 Day Avg. Volume56,077
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)2.70
Price to Sales (P/S)323.41
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-5.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue434.72
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.93
Price Target Upside166.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $4.63 and its highest was $10.75 in the past 12 months.
    What is Inmune Bio Inc’s market cap?
    Currently, no data Available
    When is Inmune Bio Inc’s upcoming earnings report date?
    Inmune Bio Inc’s upcoming earnings report date is May 18, 2023 which is in 49 days.
      How were Inmune Bio Inc’s earnings last quarter?
      Inmune Bio Inc released its earnings results on Mar 02, 2023. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.165.
        Is Inmune Bio Inc overvalued?
        According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Inmune Bio Inc pay dividends?
          Inmune Bio Inc does not currently pay dividends.
          What is Inmune Bio Inc’s EPS estimate?
          Inmune Bio Inc’s EPS estimate is -$0.02.
            How many shares outstanding does Inmune Bio Inc have?
            Inmune Bio Inc has 17,945,995 shares outstanding.
              What happened to Inmune Bio Inc’s price movement after its last earnings report?
              Inmune Bio Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -7.309%.
                Which hedge fund is a major shareholder of Inmune Bio Inc?
                Currently, no hedge funds are holding shares in INMB


                Inmune Bio Stock Smart Score

                The Inmune Bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Inmune Bio Inc

                Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.


                Top 5 ETFs holding INMB

                Market Value
                Smart Score
                Fidelity Nasdaq Composite Index ETF
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold INMB. The ETFs are listed according to market value of INMB within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                KalVista Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis